Coherus BioSciences

Rank#9156

Market Cap188.49M

CountryUnited States

Summary

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

History

Coherus BioSciences was founded in 2010 by former Amgen and Biogen Idec colleagues to pursue opportunities in the global biosimilars market. From the beginning, Coherus combined a deep understanding of biologics development and a global mindset to build a leading company in the biosimilars space.

Mission

Coherus is committed to providing world-class biopharmaceuticals to improve the lives of patients worldwide.

Vision

Our vision is to become a worldwide leader in the development, manufacturing and commercialization of innovative, affordable biopharmaceuticals.

References

https://in.investing.com/equities/charming-shoppes

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/coherus-biosciences

https://finance.yahoo.com/quote/CHRS/

https://www.coherus.com

https://sec.report/CIK/0001512762

Leadership team